Search

Your search keyword '"Ke, Zhi-Yong"' showing total 11 results
Start Over Author "Ke, Zhi-Yong" Publication Year Range Last 10 years
11 results on '"Ke, Zhi-Yong"'

3. Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways

Author

Tang, Yan-Lai, primary, Sun, Xi, additional, Huang, Li-Bin, additional, Liu, Xiao-Jian, additional, Qin, Ge, additional, Wang, Li-Na, additional, Zhang, Xiao-Li, additional, Ke, Zhi-Yong, additional, Luo, Jie-Si, additional, Liang, Cong, additional, Peng, Chun-Jin, additional, Tang, Wen-Yan, additional, Li, Yu, additional, Huang, Wenlin, additional, Luo, Xue-Qun, additional, and Deng, Wuguo, additional

Published
2019
Full Text
View/download PDF

4. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalisformula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study

Author

Yang, Ming-Hua, primary, Wan, Wu-Qing, additional, Luo, Jie-Si, additional, Zheng, Min-Cui, additional, Huang, Ke, additional, Yang, Li-Hua, additional, Mai, Hui-Rong, additional, Li, Jian, additional, Chen, Hui-Qin, additional, Sun, Xiao-Fei, additional, Liu, Ri-Yang, additional, Chen, Guo-Hua, additional, Feng, Xiaoqin, additional, Ke, Zhi-Yong, additional, Li, Bin, additional, Tang, Yan-Lai, additional, Huang, Li-Bin, additional, and Luo, Xue-Qun, additional

Published
2018
Full Text
View/download PDF

7. Multicenter randomized trial of arsenic trioxide and Realgar‐Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG‐APL clinical study.

Author

Yang, Ming‐Hua, Wan, Wu‐Qing, Luo, Jie‐Si, Zheng, Min‐Cui, Huang, Ke, Yang, Li‐Hua, Mai, Hui‐Rong, Li, Jian, Chen, Hui‐Qin, Sun, Xiao‐Fei, Liu, Ri‐Yang, Chen, Guo‐Hua, Feng, Xiaoqin, Ke, Zhi‐Yong, Li, Bin, Tang, Yan‐Lai, Huang, Li‐Bin, and Luo, Xue‐Qun

Published
2018
Full Text
View/download PDF

8. Butein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathway

Author

Tang, Yan-Lai, primary, Huang, Li-Bin, additional, Lin, Wen-Hao, additional, Wang, Li-Na, additional, Tian, Yun, additional, Shi, Dingbo, additional, Wang, Jingshu, additional, Qin, Ge, additional, Li, Anchuan, additional, Liang, Yan-Ni, additional, Zhou, Huan-Juan, additional, Ke, Zhi-Yong, additional, Huang, Wenlin, additional, Deng, Wuguo, additional, and Luo, Xue-Qun, additional

Published
2016
Full Text
View/download PDF

11. Intensive chemotherapy with dual induction and ALL-like consolidation for childhood acute myeloid leukemia: a respective report from multiple centers in China.

Author

Li JN, Chen YJ, Fan Z, Li QR, Liao LH, Ke ZY, Li Y, Wang LN, Yang CY, Luo XQ, Tang YL, Zhang XL, and Huang LB

Abstract

Background: Pediatric acute myeloid leukemia (AML) has poor prognosis and high rate of relapse and mortality, and exploration of new treatment options is still critically needed., Objectives: To summarize the outcome of our new treatment strategies for pediatric AML, which is characterized by dual induction and acute lymphoblastic leukemia (ALL) elements consolidation., Design: Retrospective, single-arm study., Methods: From July 2012 to December 2019, an intensive chemotherapy protocol was used for newly diagnosed children with AML, which contains dual induction, three courses of consolidations based on high-dose cytarabine, and two courses of consolidations composed of high-dose methotrexate, vincristine, asparaginase, and mercaptopurine (ALL-like elements). Blasts were monitored by bone marrow smears at intervals, and two lumbar punctures were performed during chemotherapy. We retrospectively analyzed the efficacy and safety of this study. The last follow-up was on 26 May 2023., Results: A total of 70 pediatric AMLs were included. The median age at diagnosis was 6.7 (0.5-16.0) years. The median initial WBC count was 23.74 × 10 9 /L, 11 of whom ⩾100 × 10 9 /L. After dual induction, there were 62 cases of complete remission (CR), 5 cases of partial remission, and 3 cases of nonremission. The CR rate was 88.57%. The median follow-up time was 5.8 (0.2-9.4) years, the 5-year overall survival was 78.2% ± 5%, the event-free survival (EFS) was 71.2% ± 5.6%, and the cumulative recurrence rate was 27.75%. The 5-year EFS of patients with initial WBC < 100 × 10 9 /L ( n  = 59) and ⩾100 × 10 9 /L ( n  = 11) were 76.4% ± 5.7% and 45.5% ± 15% ( p  = 0.013), respectively. A total of 650 hospital infections occurred. The main causes of infection were respiratory tract infection (26.92%), septicemia (18.46%), stomatitis (11.85%), and skin and soft-tissue infection (10.46%)., Conclusion: This intensive treatment protocol with dual induction and ALL-like elements is effective and safe for childhood AML. Initial WBC ⩾ 100 × 10 9 /L was the only independent risk factor in this cohort., Trial Registration: It is a retrospective study, and no registration on ClinicalTrials.gov., Competing Interests: The authors declare that there is no conflict of interest., (© The Author(s), 2024.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results